Poly(dipeptide) as a drug carrier
CA 2369029 A1 · Owner: Hande Laboratories, Inc. · Inventors: Xu, Jingya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel polypeptide drug carrier is provided wherein polypeptides containing glutamic acid and aspartic acid, or glutamic acid/alanine or glutamic , acid/asparagine, or glutamic acid/glutamine or glutamic acid/glycine, are , conjugated to drugs in order to improve the solubility of the drugs and/or their therapeutic efficacy in vivo. An illustrative example involves the conjugation of paclitaxel to a poly(glutamic acid/aspartic acid) polypeptide and its efficacy in the treatment of prostate cancer in vivo.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 13, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 13, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 13, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.